Amgen’s Kyprolis, J&J’s Darzalex team up on myeloma survival win
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data
Tag: carfilzomib
FDA Approves KYPROLIS® (carfilzomib) In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)